Greenyn Biotechnology Co (ROCO:6846) COGS-to-Revenue : 0.53 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co COGS-to-Revenue?

Greenyn Biotechnology Co's Cost of Goods Sold for the three months ended in Mar. 2024 was NT$119.7 Mil. Its Revenue for the three months ended in Mar. 2024 was NT$226.2 Mil.

Greenyn Biotechnology Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.53.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Greenyn Biotechnology Co's Gross Margin % for the three months ended in Mar. 2024 was 47.05%.

Greenyn Biotechnology Co COGS-to-Revenue Historical Data

The historical data trend for Greenyn Biotechnology Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co COGS-to-Revenue Chart

Greenyn Biotechnology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.47

0.49

0.48

0.47

0.51

Greenyn Biotechnology Co Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial										0.51	0.50	0.52	0.52	0.53

Greenyn Biotechnology Co COGS-to-Revenue Calculation

Greenyn Biotechnology Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	408.054	/	800.511
	=	0.51

Greenyn Biotechnology Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	119.748	/	226.161
	=	0.53

Greenyn Biotechnology Co (ROCO:6846) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Greenyn Biotechnology Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	119.748 / 226.161
	=	47.05 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Greenyn Biotechnology Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Greenyn Biotechnology Co (ROCO:6846) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

5th Floor, No 43 Keya Road, Daya District, Taichung, TWN

Website

https://www.greenynbio.com

Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines